BTMD biote Corp.
USHealthcareAs of 2026-07-10 16:00
Why BTMD matters now
biote Corp. (BTMD) is a US stock in Healthcare. The latest InvestLog snapshot shows $2.33 with +2.19% on the session and $102.8M in market capitalization; recent performance reads 1-month +14.14% and YTD -13.08%.
The latest financial table shown here is Q1 2026, with revenue of $44.9M, net income of $2.3M, and EPS of $0.06. Investors can compare that operating picture with valuation signals such as P/E 2.59 and FCF yield 28.0%.
The latest indexable market news headline is "Biote Appoints Komal Bajaj, MD, MS as Chief Medical Officer" from Business Wire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $3.25; recent insider activity includes Peterson Robert Charles filing A-Award. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
2.59
PEG
0.00
P/B
-1.23
P/S
0.53
EV/EBITDA
5.44
DCF Value
$8.67
FCF Yield
28.0%
Div Yield
0.0%
Margins & Returns
Gross Margin
68.5%
Operating Margin
17.0%
Net Margin
8.3%
ROE
-22.9%
ROA
17.5%
ROIC
37.1%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $44.9M | $2.3M | $0.06 |
| Q4 2025 | $46.4M | $2.0M | $0.06 |
| FY 2025 | $192.2M | $27.0M | $0.74 |
| Q3 2025 | $48.0M | $8.2M | $0.22 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$3.25
Target (Median)
$3.25
Target Range
$2.50 - $4.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Medical - Care Facilities
Country
US
Exchange
—
Beta
1.66
Biote Corp. is dedicated to supporting and developing medical practices that focus on hormone optimization. The company provides a comprehensive system for its Biote-certified healthcare professionals, enabling them to correct imbalances in patients' hormone, vitamin, and mineral levels. This includes authorizing the prescription of bioidentical hormone treatments and suggesting suitable dietary supplements. Furthermore, Biote offers its own line of branded nutritional supplements and supplies sterile kits for inserting hormone pellets for both male and female individuals. Founded in 2011, Biote Corp. is based in Irvine, Texas.